

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [REDACTED] and assuming the [REDACTED] is not exercised and no other changes are made to the issued share capital of our Company between the Latest Practicable Date and the [REDACTED], the following persons will have an interest and/or short position in the Shares or the underlying Shares which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly interested in 5% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at Shareholders’ meetings of our Company:

Name of Shareholder	Nature of Interest	Description of Shares	As of the Latest Practicable Date		Immediately following the [REDACTED] (assuming the [REDACTED] is not exercised and no new Shares are issued under the Restricted Share Incentive Schemes)		
			Number of Shares ⁽¹⁾	Approximate percentage of shareholding in our Company ⁽²⁾	Number of Shares ⁽¹⁾	Approximate percentage of shareholding in our A Shares ⁽³⁾	Approximate percentage of shareholding in our Company ⁽³⁾
Dr. Wang ⁽⁴⁾	Interest in controlled corporations	A Shares	110,329,937	19.04%	[REDACTED]	[REDACTED]%	[REDACTED]%
Aargletschers ⁽⁴⁾	Interest in controlled corporations	A Shares	110,329,937	19.04%	[REDACTED]	[REDACTED]%	[REDACTED]%
InventisBio Cayman ⁽⁴⁾	Interest in controlled corporations	A Shares	110,329,937	19.04%	[REDACTED]	[REDACTED]%	[REDACTED]%
InventisBio HK ⁽⁴⁾	Beneficial owner	A Shares	110,329,937	19.04%	[REDACTED]	[REDACTED]%	[REDACTED]%

Notes:

- (1) All interests stated are long positions in the Shares.
- (2) The calculation is based on the total number of 579,592,004 A Shares in issue as of the Latest Practicable Date.
- (3) The calculation is based on the total number of [579,592,004] A Shares and [REDACTED] H Shares in issue immediately after completion of the [REDACTED] since [REDACTED] H Shares will be issued pursuant to the [REDACTED], assuming that the [REDACTED] is not exercised, no other changes are made to the issued share capital of our Company between the Latest Practicable Date and the [REDACTED], and no new Shares are issued under the Restricted Share Incentive Schemes.
- (4) As of the Latest Practicable Date, InventisBio HK held 110,329,937 A Shares. InventisBio HK is wholly-owned by InventisBio Cayman, which is owned (a) indirectly as to 42.86% by Aargletschers, a company wholly owned by Dr. Wang, and (b) 57.14% directly by Dr. Wang. By virtue of the SFO, each of Dr. Wang, InventisBio Cayman and Aargletschers is deemed to be interested in the Shares held by InventisBio HK. See “Relationship with Our Single Largest Group of Shareholders — Our Single Largest Group of Shareholders” for more details.

Save as disclosed above and the section headed “Appendix IV — Statutory and General Information — Further Information about our Directors, Senior Management and Substantial Shareholders,” our Directors are not aware of any person who will, immediately following completion of the [REDACTED] (assuming that the [REDACTED] is not exercised and no other changes are made to the issued share capital of our Company between the Latest Practicable Date and the [REDACTED]), have any interest and/or short position in the Shares or underlying Shares of our Company which will be required to be disclosed to our Company and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who are, directly or indirectly interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at Shareholders’ meeting of the Company or any other member of our Group.